| Title |
Kidney injuries related to ipilimumab
|
|---|---|
| Published in |
Investigational New Drugs, April 2014
|
| DOI | 10.1007/s10637-014-0092-7 |
| Pubmed ID | |
| Authors |
Hassane Izzedine, Victor Gueutin, Chems Gharbi, Christine Mateus, Caroline Robert, Emilie Routier, Marina Thomas, Alain Baumelou, Philippe Rouvier |
| Abstract |
Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152) have been investigated in metastatic melanoma and other cancers and have shown promising results. Inhibition of CTLA-4 characteristically induces well-known side effects called "immune-related adverse events" (irAEs). IrAEs mainly include colitis, dermatitis, hepatitis, endocrinopathies; uveitis, iridocyclitis, neuropathies, and inflammatory myopathy have occasionally been reported. Kidney involvement is rare. We report 2 cases of acute granulomatous interstitial nephritis and present, based on literature review, renal disorders related to Ipilimumab therapy. Autoimmune symptoms have to be carefully checked for patients treated with CTLA-4 inhibitors. In order to reduce the risk of sequelae, early recognition of irAEs and treatment initiation are crucial. |
Mendeley readers
The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Unknown | 74 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 13% |
| Student > Ph. D. Student | 10 | 13% |
| Other | 9 | 12% |
| Student > Bachelor | 8 | 11% |
| Student > Doctoral Student | 5 | 7% |
| Other | 9 | 12% |
| Unknown | 24 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 40% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Agricultural and Biological Sciences | 3 | 4% |
| Immunology and Microbiology | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Other | 6 | 8% |
| Unknown | 28 | 37% |